Literature DB >> 7515371

Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate.

K W Schmid1, B Helpap, M Tötsch, R Kirchmair, B Dockhorn-Dworniczak, W Böcker, R Fischer-Colbrie.   

Abstract

Routinely processed normal, hyperplastic and neoplastic prostatic tissue was immunohistochemically investigated with antibodies against chromogranin A and B and secretogranin II. In normal and hyperplastic prostates all three peptides were immunolocalized in scattered neuroendocrine cells situated within the glandular epithelium. In 17 prostatic carcinomas with pronounced neuroendocrine differentiation and in a case of prostatic carcinoid, chromogranin B was the major component whereas chromogranin A and secretogranin II were virtually absent in poorly differentiated (grade III) tumours. Neuroendocrine differentiation in prostatic cancer is most likely to be associated with a poor clinical outcome; thus, chromogranin B appears to be a useful marker in the histopathological diagnosis of these neoplasms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515371     DOI: 10.1111/j.1365-2559.1994.tb00515.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

1.  Immunohistochemical demonstration of chromogranin A, chromogranin B, and secretoneurin in primary non-small-cell carcinomas of the lung.

Authors:  Martin Tötsch; Birgit Kunk; Barbara Dockhorn-Dworniczak; Dietmar Öfner; Reiner Fischer-Colbrie; Gregor Mikuz; Werner Böcker; Kurt Werner Schmid
Journal:  Endocr Pathol       Date:  1994-12       Impact factor: 3.943

2.  Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model.

Authors:  J Jongsma; M H Oomen; M A Noordzij; W M Van Weerden; G J Martens; T H van der Kwast; F H Schröder; G J van Steenbrugge
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

3.  Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.

Authors:  Allison B Weisbrod; Lisa Zhang; Meenu Jain; Stephanie Barak; Martha M Quezado; Electron Kebebew
Journal:  Horm Cancer       Date:  2013-01-30       Impact factor: 3.869

Review 4.  Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate.

Authors:  M A Noordzij; G J van Steenbrugge; T H van der Kwast; F H Schröder
Journal:  Urol Res       Date:  1995

5.  Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells.

Authors:  M E Harper; E Glynne-Jones; L Goddard; V J Thurston; K Griffiths
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.